Vaccines are a major contribution to global health and their manufacturing can be complex due to their diversity and inherent properties. Such complexity is exacerbated in outbreaks and pandemics and thus the traditional development and manufacturing paradigm is no longer valid. In the last decade, outbreaks and pandemics of H1N1 Influenza, Ebola, MERS, Zika and now SARS-Cov2 (COVID19) have heavily influenced vaccine manufacturing and lessons learned have allowed to improve our general response to high surge of vaccines. Despite of that, there are remaining issues around process development, manufacturing processes and capacity. How can vaccine manufacturing evolve to increase efficiency, speed and global access? What does the vaccine facility of the future could look like and how platforming vaccines can help addressing future global health challenges?